Systemic thromboembolism in inflammatory bowel disease: Mechanisms and clinical applications

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 166-173

  Twig, Gilad ^a   Zandman Goddard, Gisele ^a   Szyper Kravitz, Martine ^a   Shoenfeld, Yehuda ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Homocysteinemia; Hypercoagulable state; Inflammatory bowel disease; Thrombosis

Indexed keywords

BLOOD CLOTTING; CLINICAL FEATURE; CONFERENCE PAPER; ENTERITIS; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERHOMOCYSTEINEMIA; INFLAMMATION; PRIMARY PREVENTION; SECONDARY PREVENTION; THROMBOCYTE; THROMBOEMBOLISM;

EID: 25444497459     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.058     Document Type: Conference Paper

References (45)

1. BARGEN, J.A. & N.W. BARKER. 1936. Extensive arterial and venous thrombosis complicating ulcerative colitis. Arch. Intern. Med. 58: 17-31.
2. WAKEFIELD, A.J. et al. 1989. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 334: 1057-1062.
3. MIEHSLER, W. et al. 2004. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut 53: 542-548.
4. BERNSTEIN, C.N., J.F. BLANCHARD, D.F. HOUSTON & A. WAJDA. 2001. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 85: 430-434.
5. TALBOT, R.W., J. HEPPELL, R.R. DOZOIS & R.W. BEART, JR. 1986. Vascular complications of inflammatory bowel disease. Mayo Clin. Proc. 61: 140-145.
6. JACKSON, L.M. et al. 1997. Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 90: 183-188.
7. SOLEM, C.A., E.V. LOFTUS, W.J. TREMAINE & W.J. SANDBORN. 2004. Venous thromboembolism in inflammatory bowel disease. Am. J. Gastroenterol. 99: 97-101.
8. GRAEF, V. et al. 1965. Venous thrombosis occurring in non-specific ulcerative colitis. Arch. Intern. Med. 117: 377-382.
9. NOVACEK, G. et al. 2004. Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm. Bowel Dis. 10: 430-435.
10. MURATA, S. et al. 2004. Cerebral sinus thrombosis associated with severe active ulcerative colitis. Intern. Med. 43: 400-403.
11. OLDENBURG, B. et al. 2000. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am. J. Gastroenterol. 95: 2825-2830.
12. SAIBENI, S., L. SPINA & M. VECCHI. 2004. Exploring the relationships between inflammatory response and coagulation cascade in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 8: 205-208.
13. SOUTO, J.C. et al. 1995. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig. Dis. Sci. 40: 1883-1889.
14. HOMMES, D.W. et al. 1997. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis 27: 269-277.
15. GAFFNEY, P.R. et al. 1995. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am. J. Gastroenterol. 90: 220-223.
16. WEBBERLEY, M.J., M.T. HART & V. MELIKIAN. 1993. Thromboembolism in inflammatory bowel disease: role of platelets. Gut 34: 247-251.
17. CHIARANTINI, E. et al. 1996. Hemostatic abnormalities in inflammatory bowel disease. Thromb. Res. 82: 137-146.
18. LIBBY, P. 2003. Vascular biology of atherosclerosis: overview and state of the art. Am. J. Cardiol. 91: 3A-6A.
19. DANESE, S. et al. 2003. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52: 1435-1441.
20. VARO, N. et al. 2003. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108: 1049-1052.
21. KOUTROUBAKIS, I.E. et al. 2004. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 16: 1147-1152.
22. MCCULLY, K.S. 1996. Homocysteine and vascular disease. Nat. Med. 2: 386-389.
23. SAIBENI, S. et al. 2003. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am. J. Gastroenterol. 98: 112-117.
24. ROMAGNUOLO, J. et al. 2001. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am. J. Gastroenterol. 96: 2143-2149.
25. LASHNER, B.A. et al. 1989. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 97: 255-259.
26. CATTANEO, M. et al. 1998. High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb. Haemost. 80: 542-545.
27. CHAMOUARD, P. et al. 1995. Prothrombin fragment 1 +,2 and thrombin-antithrombin III complex as markers of activation of blood coagulation in inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 7: 1183-1188.
28. LAKE, A.M., J.Q. STAUFFER & M.J. STUART. 1978. Hemostatic alterations in inflammatory bowel disease: response to therapy. Am. J. Dig. Dis. 23: 897-902.
29. JORENS, P.G. et al. 1990. Acquired protein C and S deficiency, inflammatory bowel disease and cerebral arterial thrombosis. Blut 61: 307-310.
30. LARSEN, T.B. et al. 2002. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol. Haemost. Thromb. 32: 92-96.
31. WYSHOCK, E., M. CALDWELL & J.P. CROWLEY. 1988. Deep venous thrombosis, inflammatory bowel disease, and protein S deficiency. Am. J. Clin. Pathol. 90: 633-635.
32. KOUTROUBAKIS, I.E. et al. 2000. Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. Am. J. Gastroenterol. 95: 190-194.
33. SAIBENI, S. et al. 2001. Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies. Dig. Dis. Sci. 46: 637-643.
34. FAIONI, E.M. et al. 2004. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit. Care Med. 32: S266-270.
35. PAPA, A. et al. 2003. Review article: inherited thrombophilia in inflammatory bowel disease. Am. J. Gastroenterol. 98: 1247-1251.
36. GRIS, J.C. et al. 1990. Impaired fibrinolytic capacity in patients with inflammatory bowel disease. Thromb. Haemost. 63: 472-475.
37. SAIBENI, S. et al. 2004. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am. J. Gastroenterol. 99: 1966-1970.
38. KOUTROUBAKIS, I.E. 2000. Role of thrombotic vascular risk factors in inflammatory bowel disease. Dig. Dis. 18: 161-167.
39. KOUTROUBAKIS, I.E. et al. 1998. Anti-cardiolipin and anti-beta2- glycoprotein I antibodies in patients with inflammatory bowel disease. Dig. Dis. Sci. 43: 2507-2512.
40. HENEGHAN, M.A. et al. 1998. Activated protein C resistance, thrombophilia, and inflammatory bowel disease. Dig. Dis. Sci. 43: 1356-1361.
41. WAKEFIELD, A.J. et al. 1991. Smoking, the oral contraceptive pill, and Crohn's disease. Dig. Dis. Sci. 36: 1147-1150.
42. VRIJ, A.A. et al. 2001. Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand. J. Gastroenterol, Suppl. 234: 41-47.
43. KAO, A. et al. 2002. Anticoagulation therapy in cerebral sinovenous thrombosis and ulcerative colitis in children. J. Child Neurol. 17: 479-482.
44. AGENO, W. et al. 2002. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 87: 746-750; discussion 250.
45. TYRRELL, D.J. et al. 1999. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv. Pharmacol. 46: 151-208.